ACLARUSDX
LIVE

Serial Number

79091998

Owner

EXONHIT S.A.

Filing Date

Aug 24, 2010

Add to watchlist:

No watchlists yet
View on USPTO

ACLARUSDX Trademark

Serial Number: 79091998 • Registration: 4024702

ACLARUSDX is a trademark filed by EXONHIT S.A. on August 24, 2010. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

EXONHIT S.A. (5 trademarks)

63-65 BOULEVARD MASSENA
PARIS 75013 , FR

Entity Type: 11

ExonHit Therapeutics (3 trademarks)

26, rue Brunel

Entity Type: 99

Trademark Details

Filing Date

August 24, 2010

Registration Date

September 13, 2011

Published for Opposition

June 28, 2011

Cancellation Date

August 24, 2020

Goods & Services

Pharmaceutical preparations for treating neurodegenerative diseases, particularly Alzheimer's disease; diagnostic reagents and media for medical use, namely, reagents and media for use in testing blood biomarkers, to enable the identification of patients suffering from Alzheimer's disease or at risk of developing the disease and for enabling the identification of patients responding to specific treatments; acidic biological preparations and products for pharmaceutical purposes, namely, pharmaceutical preparations for diagnosing Alzheimer's disease; capsules for diagnostic tests and medicines sold empty; chemico-pharmaceutical preparations for diagnosing, preventing and treating Alzheimer's disease; biopharmaceutical preparations for diagnosing, preventing and treating Alzheimer's disease; chemicals for medical, pharmaceutical or veterinary purposes, namely, chemicals for diagnosing neurodegenerative diseases, especially Alzheimer's disease; medical and clinical diagnosis testing kits comprised of nucleic acid banks, nucleic acids on DNA chips and testing probes; DNA libraries and RNA libraries for medical diagnostic purposes; nucleic acid sequences for use on biochips, for medical and medical diagnostic use, namely, for decoding genes affected by Alzheimer's disease or revealing the transcriptomic signature of patients suffering from Alzheimer's disease; enzymes or enzyme preparations for medical or veterinary purposes, namely, enzyme stabilizers and enzyme substrates used as ingredients in medicines for treatment of Alzheimer's disease; reagents contained in diagnostic test kits for taking blood samples, for the preservation of the biological material under analysis in order to carry out the test under the appropriate conditions

Chemical preparations and compositions, namely, nucleic acids attached to a solid medium, for industrial and scientific use; chemical fissile preparations for laboratory use; chemical fissile preparations for scientific research; chemical preparations for nucleic acids attached to a solid medium, other than for medical or veterinary purposes; biological preparations, other than for medical or veterinary purposes, namely, blood for enabling the quantification of nucleic acid content; chemicals for scientific use, other than for medical or veterinary purposes; chemical preparations or reagents for laboratory, namely, nucleic acid to screen and analyze gene expression, to identify therapeutic targets and products, and to conduct pharmacogenomic and genotoxicity research in the fields of pharmacology, food, chemistry, cosmetology, plant protection, and veterinary sciences; chemical preparations for scientific use, namely, nucleic acid libraries to screen and analyze gene expression, to identify therapeutic targets and products, and to conduct pharmacogenomic and genotoxicity research in the fields of pharmacology, food, chemistry, cosmetology, plant protection, and veterinary sciences; chemical preparations for scientific use, namely, DNA biochips for decoding genes affected by the Alzheimer's disease or revealing the transcriptomic signature of patients affected with Alzheimer's disease, and DNA chips to make visible and analyze gene expression in the fields of human and pharmacological medicine and veterinary science

Medical services; veterinary services; medical assistance; consulting in the fields of biotechnology and pharmacy, namely, to assist in the selection of Alzheimer's sufferers for clinical trials and to offer personalized treatments; hospitals; pharmacist's services to make up prescriptions; pharmaceutical advice; medical services, namely, facilitating the diagnosis and care of geriatric patients and patients with neurodegenerative diseases; health care; telemedicine services

Surgical, medical, dental and veterinary apparatus and instruments, namely, apparatus and instruments for use in identifying, assessing the seriousness of, assessing the prognoses of, measuring the progression of and measuring the conversion of neurodegenerative diseases such as Alzheimer's; medical apparatus using DNA chips for analyzing blood; apparatus for analyzing blood; apparatus for medical diagnostic purposes, namely, kits for taking blood samples comprising medical instruments for taking blood, DNA chips for diagnosing Alzheimer's disease, and material required for the preservation of the biological material under analysis in order to carry out the test under the appropriate conditions; spoons for medicines; containers specially adapted for the application of medicines, namely, bags and pouches used in the delivery of medication; probes for medical purposes; syringes for medical purposes; galvanic therapeutic devices for diagnosing neurodegenerative diseases, especially Alzheimer's disease

Research and development for others of pharmaceutical molecules or biological markers and medicines for diagnosing and treating neurodegenerative diseases; chemical analyses; chemical research; chemical services, namely, analysis of RNA genes, tissues, and blood samples; biotechnological project studies to identify people suffering from Alzheimer's disease and to measure the seriousness, prognoses, progression and conversion of the disease and to determine how patients respond to treatments; research and development of new products for others; biological research; biotechnological research; technical research in the field of biotechnology; biotechnological analysis services; laboratory analyses, namely, quantification of nucleic acid content for medical and scientific research purposes

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Sep 10, 2021 DENC
DEATH OF INTERNATIONAL REGISTRATION
Sep 10, 2021 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Sep 25, 2015 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Sep 2, 2015 INTS
INVALIDATION PROCESSED
Sep 2, 2015 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Aug 5, 2015 INTR
CANCELLED SECTION 7-TOTAL
Dec 5, 2014 C7..
CANCELLATION TERMINATED NO. 999999
Dec 5, 2014 CANT
CANCELLATION DENIED NO. 999999
Dec 3, 2014 CAND
CANCELLATION INSTITUTED NO. 999999
Oct 24, 2014 PETC
FINAL DECISION TRANSACTION PROCESSED BY IB
May 19, 2013 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 23, 2011 FICS
FINAL DISPOSITION PROCESSED
Dec 23, 2011 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 13, 2011 FICR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Oct 15, 2011 ADCH
REGISTERED-PRINCIPAL REGISTER
Sep 13, 2011 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 28, 2011 NPUB
PUBLISHED FOR OPPOSITION
Jun 28, 2011 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
May 26, 2011 PREV
ASSIGNED TO LIE
May 26, 2011 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
May 12, 2011 CNSA
EXAMINER'S AMENDMENT ENTERED
May 12, 2011 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 12, 2011 GNEN
EXAMINERS AMENDMENT E-MAILED
May 12, 2011 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 12, 2011 CNEA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 26, 2011 TCCA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 26, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 26, 2011 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 26, 2011 TROA
REFUSAL PROCESSED BY IB
Feb 27, 2011 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 9, 2011 RFCS
REFUSAL PROCESSED BY MPU
Feb 9, 2011 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 9, 2011 RFCR
NON-FINAL ACTION WRITTEN
Feb 8, 2011 CNRT
APPLICATION FILING RECEIPT MAILED
Feb 8, 2011 MAFR
ASSIGNED TO EXAMINER
Feb 4, 2011 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 4, 2011 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 3, 2011 REPR